Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gs-9256. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gs-9256 SCHEMBL19151837 | 1.00 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| Gs-9256 SCHEMBL15258587 | 1.00 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| SCHEMBL22484285 | 1.00 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| Gs-9256 SCHEMBL15444521 | 1.00 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| Gs-9256 SCHEMBL9987287 | 1.00 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| SCHEMBL12732537 | 0.97 | ADRB3 (0.54) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| SCHEMBL12731895 | 0.96 | ADRB3 (0.57) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| SCHEMBL12864482 | 0.95 | ADRB3 (0.54) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| SCHEMBL12732545 | 0.95 | ADRB3 (0.63) | ADRB3ADRA2BADRA2CABCC1ABCC2 | |
| SCHEMBL12732369 | 0.95 | ADRB3 (0.58) | ADRB3ADRA2BADRA2CABCC1ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-25 | — | — | US | disclosed |
| US-11572565-B2 | Inducible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-02-07 | — | — | US | disclosed |
| US-11530246-B2 | Regulated synthetic gene expression systems | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220025381-A1 | INDUCIBLE CONTROL OF GENE EXPRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-01-27 | — | — | US | disclosed |
| US-11116783-B2 | Combination formulation of two antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210000854-A1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159600-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | ADRB3 4589/4885ADRA2B 4590/4885ADRA2C 4561/4885 |
| US-11116783-B2 | Combination formulation of two antiviral compounds | EIF2AK2, SARS1, ZC3HAV1 | ADRB3 3055/4885ADRA2B 2858/4885ADRA2C 3137/4885 |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | ATF4, MRPL21, TMPRSS2 | ADRB3 1423/4885ADRA2B 1976/4885ADRA2C 1911/4885 |
| US-11530246-B2 | Regulated synthetic gene expression systems | SRRT, BPTF, MYCBP | ADRB3 4589/4885ADRA2B 4590/4885ADRA2C 4561/4885 |
| US-20200377564-A1 | REGULATED SYNTHETIC GENE EXPRESSION SYSTEMS | SRRT, BPTF, MYCBP | ADRB3 4589/4885ADRA2B 4590/4885ADRA2C 4561/4885 |
| US-20210000854-A1 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS | EIF2AK2, SARS1, ZC3HAV1 | ADRB3 3055/4885ADRA2B 2858/4885ADRA2C 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.